Active Ingredient(s): Abciximab
FDA Approved: * December 16, 2003
Pharm Company: * CENTOCOR INC
Category: Blood Thinner (Anticoagulant)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

ReoPro Overview

Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[3] While abciximab has a short plasma half-life, due to its stron...

Read more ReoPro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent ReoPro Forums: RSS Feed


Blood Thinner ## I am not sure if this helps but you might find information on ReoPro® (chemical name Abciximab) useful; This drug acts as a platelet aggregation inhibitor (blood thinning agent) during surgical procedures. ## Yes, ReoPro® is a monoclonal antibody directed against platelet receptors. Is Monoclore an actual trade or chemical name for another drug? If so, which country?


Possible Dosages for this and Related Drugs:

  • Injection: 2mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for ReoPro: (2 results)

Sorted by National Drug Code
  • 0002-7140 Reopro 2 mg/ml Intravenous Injection, Solution by Eli Lilly and Company
  • 57894-200 Reopro 2 mg/ml Intravenous Injection, Solution by Janssen Biotech, Inc.

Other drugs which contain Abciximab or a similar ingredient: (1 result)

Related ReoPro Topics:

reopro (abciximab) for cardiac ischemic complications
ReoPro(Abciximab) is a monoclonal antibody that blocks the pathway to platelet aggregation and reduces cardiac ischemic ...